Why the study?
Postoperative atrial fibrillation affects nearly 40% of patients and increases adverse outcomes, yet controversies persist regarding anticoagulation for short-lived episodes and identifying candidates for preventive therapy.
This review summarizes the pathophysiology, management, and preventive strategies for postoperative atrial fibrillation, a common complication affecting nearly 40% of patients.
Answers are grounded in this paper and cite their sources.
POAF's morbidity burden warrants perioperative vigilance; leaves open optimal prevention strategies pending higher-quality trials.
Atrial fibrillation (AF) in the postoperative phase is a manifestation of numerous factors, including surgical stress, anesthetic effects, and underlying cardiovascular conditions. The resultant cardiac hyperactivity can induce new onset or exacerbate existing AF. A common phenomenon, postoperative atrial fibrillation (POAF) affects nearly 40% of patients and is associated with longer hospitalization stays, and increased mortality, heart failure, stroke, and healthcare costs. Areas of controversy in POAF include whether to anticoagulate patients who have short-lived POAF, especially given their higher bleeding risk in the postoperative period, and the identification of patients who would benefit the most from preventive drug therapy for POAF. This review discusses the pathophysiology and management of POAF, and strategies to reduce its occurrence.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: